The FDA has rejected Pharming’s application to expand the licence of Ruconest, for a use as prophylaxis for patients with the serious rare disease hereditary angioedema (HAE).
AstraZeneca is planning to expand its role as a drug supplier in China to becoming a wider provider of healthcare through its use of robotics and other tech.
